18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival
European Journal of Nuclear Medicine and Molecular Imaging · 2025-12 · 53 (1) · 374-388
DOI: 10.1007/s00259-025-07459-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 19.07.2025. Verfasst von Yizhao Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron Emission Tomography Computed Tomography, Estradiol. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Science and Technology Innovation Medical Development Foundation, Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
BACKGROUND: While CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i+ET) have revolutionized treatment for HR+/HER2- metastatic breast cancer (MBC), inter-lesional estrogen receptor (ER) heterogeneity limits therapeutic efficacy in a subset of patients. Whole-body 18F-fluoroestradiol (18F-FES) PET/CT enables non-invasive ER quantification across all metastatic sites. However, whether 18F-FES-guided therapy selection improves clinical outcomes in relatively large sample cohorts is not yet well-established. PATIENTS AND METHODS: We screened all 1613 HR+/HER2- metastatic breast cancer (MBC) patients from 2020 to 2024 at Fudan University Shanghai Cancer Center. Patients who received standard first line treatment were enrolled in this retrospective study. RESULTS: A total of 473 patients were included in the study. 156(33.0%) and 317 (67.0%) patients were screened or unscreened by 18F-FES-PET before first-line treatment. 111 patients with all-FES positive metastatic lesions and 17 patients with FES heterogeneity received CDK4/6 inhibitors combined with endocrine therapy. 21 patients with all-FES negative metastatic lesions and 7 patients with FES heterogeneity received chemotherapy (CT). As for the unscreened group, 236 received CDK4/6 inhibitors combined with endocrine therapy and 81 received CT. In CDK4/6 inhibitors combined with endocrine therapy cohort, FES-screened group showed a significantly prolonged progression-free survival (PFS) compared with unscreened group (mPFS 32.4 months versus 17.3 months, Hazard Ratio = 0.49; 95% CI, 0.34 to 0.69; p < 0.0001). And chemotherapy cohort showed superior PFS for screened patients as well (mPFS 11.38 months versus 8.91 months, Hazard Ratio = 0.56; 95% CI, 0.33 to 0.94; p = 0.026). CONCLUSIONS: HR + /HER2- MBC patients with FES-guided initial treatment showed significantly better efficacy than those who had not been assessed by 18F-FES-PET/CT. This retrospective study highlights the crucial instructive role of FES assessment in evaluating ER expression in patients prior to administering first-line treatment. In the present study, improved PFS was observed when first-line therapy was guided by 18F-FES-PET in newly diagnosed HR+/HER2- MBC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
- Center for Biomedical Imaging, Fudan University, Shanghai, 200032, China.
- Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. shaoli-song@163.com.
ORCID-Profile: Zhongyi Yang
Förderung
- National Natural Science Foundation of China
- Beijing Science and Technology Innovation Medical Development Foundation
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Xie, Y., Chen, Y., Liu, C., Zhao, Y., Gong, C., Lin, S., Song, S., Wang, B., & Yang, Z. (2025). 18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival. European Journal of Nuclear Medicine and Molecular Imaging, 53(1), 374-388. https://doi.org/10.1007/s00259-025-07459-w
Vancouver
Xie Y, Chen Y, Liu C, Zhao Y, Gong C, Lin S, et al. 18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival. European Journal of Nuclear Medicine and Molecular Imaging. 2025;53(1):374-388. doi:10.1007/s00259-025-07459-w
BibTeX
@article{Xie2025,
author = {Xie, Yizhao and Chen, Yifan and Liu, Cheng and Zhao, Yannan and Gong, Chengcheng and Lin, Shuyi and Song, Shaoli and Wang, Biyun and Yang, Zhongyi},
title = {18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {53},
number = {1},
pages = {374--388},
doi = {10.1007/s00259-025-07459-w}
}
EUVIMED